Chemical-structure (Chemical Structure)
Sumatriptan Succinate Tablet, Film Coated
Product Images NDC 71205-274
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sumatriptan Succinate (NDC 71205-274). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
71205-274-09 (Sumatriptan Carton 100mg)
Sumatrptan Succinate 100mg tablets are a prescription medication for people suffering from migraine headaches. The tablets are triangular-shaped and pink with "S" on one side and "100" on the other. The medication is manufactured in Halol-389 350, Gujarat, India by Sun Pharmaceutical Industries Ltd. Proficent Rx LP has relabeled this drug and their offices are located in Thousand Oaks, CA 91320. It is important to keep this medication out of reach of children and to store it at a temperature between 20°-25°C (68°-77°F). No available information on how many tablets are in the box.*
Sumatriptan-figure-1 (Sumatriptan Figure 1)
The given text is a figure that displays the estimated probability of achieving headache relief within four hours of treatment with oral sumatriptan. The chart shows different dosages of the sumatriptan and the time to achieve relief. The data is based on three clinical trials providing evidence of effectiveness. Patients not achieving a response within 240 minutes were censored.*
Sumatriptan-figure-2 (Sumatriptan Figure 2)
This is a figure and table showing the estimated probability of patients taking a second dose of Sumatriptan Succinate Tablets or other medication to treat migraine over 24 hours, based on data obtained in 3 clinical controlled trials. The Kaplan-Meier plot shows that patients had a higher probability of taking a second dose within the first 2 hours after the initial dose, and the likelihood decreased over time. Patients who had no response to the initial dose are also included in the plot. No remedication was allowed within 2 hours postdose.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
